Indivior surges as directors buy up shares

Indivior shares got a boost on Wednesday as the drug developer revealed that some of its directors had been buying up the stock.

The company, which makes opioid addiction treatment Suboxone, said chief executive officer Sean Thaxter bought 100,000 shares at 44.64p each, leaving him with an interest of just over 1.6 million shares.

Meanwhile, non-executive director Daniel Phelan bought 10,000 ADRs, representing 50,000 shares at an average price of $2.78 each, leaving him with an interest in 60,318 Shares.

Tatjana May, another non-executive director, bought 22,309 shares at 44.58p each, leaving her with 22,309 shares.

Indivior has come under pressure recently after it was hit with US fraud charges over a marketing scheme used to boost prescriptions of its opioid addiction drugs.

At 1425 BST, the shares were up 11.7% at 50.55p.